In:
Cancer, Wiley, Vol. 125, No. 15 ( 2019-08), p. 2602-2609
Abstract:
This clinical trial evaluates risk and response–based multi‐agent therapy for patients with rhabdomyosarcoma at first relapse. Patients with unfavorable‐risk rhabdomyosarcoma at first relapse or disease progression have a poor prognosis when they are treated with this therapy, whereas favorable‐risk patients have a higher chance of a cure with second‐line therapy.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1